A Randomized, Triple-Blind, Placebo-Controlled, Add-On Clinical Trial to Evaluate the Efficacy of Emblica officinalis in Uncontrolled Hypertension

Table 1

Baseline characteristics of participants.

	EO group (n = 41)	Control group (n = 40)	value
Age (year)	56.05 ± 10.02	51.18 ± 9.5	0.02
(mean ± SD)
Sex, n (%)	Male: 20 (48.8)	25 (62.5)	0.26
	Female: 21 (51.2)	15 (37.5)
Marriage, n (%)	Single: 0	2 (5)	0.24
	married: 41 (100)	2 (5)
BMI (mean ± SD)	28.08 (4.8)	27.04 (3.9)	0.3
Duration of HTN (months) (mean ± SD)	85.57 (83.36)	69.16 (65.25)	0.51
Duration of use of anti-HTN drugs (months) (mean ± SD)	65.47 (75.94)	60.85 (67.21)	0.84
Smoking, n (%)	7 (17.1)	11 (27.5)	0.29

EO: Emblica officinalis, SD: standard deviation, BMI: body mass index, and HTN: hypertension.